CNR1 and metabolic dysfunction-associated steatohepatitis: As a partial CB1 agonist, THC is likely to be pro-steatotic.11 Contrary to THC, CBD, a nonpsychoactive cannabinoid for which a CB1 negative allosteric modulator activity has been suggested, is a promising candidate as an antisteatotic agent,11 and has already yielded results in animal and in vitro models.28 Moreover, as an antioxidant and anti-inflammatory molecule,29–31 CBD is likely to protect the liver from progression to NASH.